Skip to main content

Advertisement

Log in

Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Juvenile idiopathic arthritis (JIA) is a heterogenous childhood disease without reliable biomarkers for monitoring disease progression. Immunoglobulin (Ig) M rheumatoid factor (RF) is used to define a subset of JIA patients, but its significance in JIA is dependent on the method of measurement. In addition to IgM RF, IgA RF has been implicated in determining disease severity in JIA, including functional disability and joint damage. Anticyclic citrullinated peptide (anti-CCP) antibodies have been a valuable diagnostic tool in rheumatoid arthritis, with varied results in their significance in JIA patients. Recent studies have demonstrated the possible usefulness of isotypes of anti-CCP antibodies in monitoring JIA patients to determine disease outcome. Overall, RF isotypes and anti-CCP isotypic antibodies have demonstrated increasing importance in the evaluation of JIA patients to determine which patients may have more aggressive or severe disease and to aid in possible treatment plans to prevent joint damage and disability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cassidy JT, Petty RE, eds: Chronic arthritis in children. In Textbook of Pediatric Rheumatology. Philadelphia: Elsevier Saunders; 2005:206–260.

  2. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Rheumatol 1998, 25:1991–1994.

    PubMed  CAS  Google Scholar 

  3. Ravelli A, Martini A: Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003, 21(5 Suppl 31):S89–S93.

    PubMed  CAS  Google Scholar 

  4. Berglin E, Johansson T, Sundin U, et al.: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453–458.

    Article  PubMed  CAS  Google Scholar 

  5. Ates A, Kinikli G, Turgay M, et al.: Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 2007, 26:538–545.

    Article  PubMed  Google Scholar 

  6. Ferreira RA, Ferriani VP, Sopelete MC, et al.: Immunoglobulin E-rheumatoid factor in juvenile rheumatoid arthritis. Rev Hosp Clin Fac Med Sao Paulo 2002, 57:209–216.

    PubMed  Google Scholar 

  7. Moore TL, Dorner RW: Rheumatoid factors. Clin Biochem 1993, 26:75–84.

    Article  PubMed  CAS  Google Scholar 

  8. Walker SM, McCurdy DK, Shaham B, et al.: High prevalence of IgA rheumatoid factor in severe polyarticular-onset juvenile rheumatoid arthritis, but not in systemic-onset or pauciarticular-onset disease. Arthritis Rheum 1990, 33:199–204.

    Article  PubMed  CAS  Google Scholar 

  9. Walker SM, Shaham B, McCurdy DK, et al.: Prevalence and concentration of IgM rheumatoid factor in polyarticular onset disease as compared to systemic or pauciarticular onset disease in active juvenile rheumatoid arthritis as measured by ELISA. J Rheumatol 1990, 17:936–940.

    PubMed  CAS  Google Scholar 

  10. Saulsbury FT: Prevalence of IgM, IgA and IgG rheumatoid factors in juvenile rheumatoid arthritis. Clin Exp Rheumatol 1990, 8:513–517.

    PubMed  CAS  Google Scholar 

  11. Jarvis JN, Pousak T, Krenz M: Detection of IgM rheumatoid factors by enzyme-linked immunosorbent assay in children with juvenile rheumatoid arthritis: correlation with articular disease and laboratory abnormalities. Pediatrics 1992, 90:945–949.

    PubMed  CAS  Google Scholar 

  12. Aggarwal A, Dabadghao S, Naik S, Misra R: Serum IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA) delineates a subset of patients with deforming joint disease in seronegative juvenile rheumatoid arthritis. Rheumatol Int 1994, 14:135–138.

    Article  PubMed  CAS  Google Scholar 

  13. Varbanova BB, Baleva M, Nikolov K, Mihailova D: Prevalence of IgM-, IgA-and IgG-rheumatoid factors in seronegative polyarticular disease compared to pauciarticular disease in juvenile chronic arthritis as measured by ELISA. Adv Exp Med Biol 1999, 455:61–68.

    PubMed  CAS  Google Scholar 

  14. Bharadwaj A, Aggarwal A, Misra R: Clinical relevance of IgA rheumatoid factor (RF) in children with juvenile rheumatoid arthritis. Rheumatol Int 1999, 19:47–49.

    Article  PubMed  CAS  Google Scholar 

  15. Bhardwaj A, Aggarwal A, Agarwal V, Misra A: Role of IgM and IgA rheumatoid factors in complement activation in patients with juvenile rheumatoid arthritis. Indian J Med Res 2000, 111:103–109.

    PubMed  CAS  Google Scholar 

  16. Ferreira RA, Silva CH, Silva DA, et al.: Is measurement of IgM and IgA rheumatoid factors (RF) in juvenile rheumatoid arthritis clinically useful? Rheumatol Int 2007, 27:345–349.

    Article  PubMed  CAS  Google Scholar 

  17. Gilliam BE, Low JM, Chauhan AK, Moore TL: Biomarkers associated with joint damage in juvenile idiopathic arthritis. Arthritis Rheum 2006, 54:S697.

    Google Scholar 

  18. Gilliam BE, Chauhan AK, Low JM, Moore TL: Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol 2008, In press.

  19. Jónsson T, Steinsson K, Jónsson H, et al.: Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity of rheumatoid arthritis. Rheumatol Int 1998, 18:119–122.

    Article  PubMed  Google Scholar 

  20. Nienhuis RL, Mandema E: A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964, 23:302–305.

    PubMed  CAS  Google Scholar 

  21. Young BJ, Mallya RK, Leslie RD, et al.: Anti-keratin antibodies in rheum atoid arthritis. Br Med J 1979, 2:97–99.

    PubMed  CAS  Google Scholar 

  22. Sebbag M, Simon M, Vincent C, et al.: The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995, 95:2672–2679.

    Article  PubMed  CAS  Google Scholar 

  23. Simon M, Girbal E, Sebbag M, et al.: The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993, 92:1387–1393.

    Article  PubMed  CAS  Google Scholar 

  24. Simon M, Vincent C, Haftek M, et al.: The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis. Clin Exp Immunol 1995, 100:90–98.

    PubMed  CAS  Google Scholar 

  25. Schellekens GA, de Jong BA, van den Hoogen FH, et al.: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273–281.

    Article  PubMed  CAS  Google Scholar 

  26. Schellekens GA, Visser H, de Jong BA, et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155–163.

    Article  PubMed  CAS  Google Scholar 

  27. Kroot EJ, de Jong BA, van Leeuwen MA, et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831–1835.

    Article  PubMed  CAS  Google Scholar 

  28. van Jaarsveld CH, ter Borg EJ, Jacobs JW, et al.: The prognostic value of the antiperinuclear factor, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999, 17:689–697.

    PubMed  Google Scholar 

  29. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al.: The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol 2001, 166:4177–4184.

    PubMed  CAS  Google Scholar 

  30. Menard HA, Lapointe E, Rochdi MD, Zhou ZJ: Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000, 2:429–432.

    Article  PubMed  CAS  Google Scholar 

  31. Baeten D, Peene I, Union A, et al.: Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001, 44:2255–2262.

    Article  PubMed  CAS  Google Scholar 

  32. Vossenaar ER, Nijenhuis S, Helsen MM, et al.: Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003, 48:2489–2500.

    Article  PubMed  CAS  Google Scholar 

  33. Hill JA, Wehrli B, Jevnikar AM, et al.: Citrullinated fibrinogen induces arthritis in HLA-DRB1*0401 transgenic mice. Arthritis Rheum 2003, 48:S348.

    Article  Google Scholar 

  34. Nesher G, Moore TL, Gristanti MW, et al.: Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis 1992, 51:350–352.

    Article  PubMed  CAS  Google Scholar 

  35. Gabay C, Prieur AM, Meyer O: Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993, 52:785–789.

    PubMed  CAS  Google Scholar 

  36. Hromadnikova I, Stechova K, Pavla V, et al.: Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 2002, 35:397–401.

    Article  PubMed  Google Scholar 

  37. Avcin T, Cimaz R, Falcini F, et al.: Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608–611.

    Article  PubMed  CAS  Google Scholar 

  38. van Rossum M, van Soesbergen R, de Kort S, et al.: Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003, 30:825–828.

    PubMed  Google Scholar 

  39. Kasapcopur O, Altun S, Aslan M, et al.: Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1687–1689.

    Article  PubMed  CAS  Google Scholar 

  40. Low JM, Chauhan AK, Kietz DA, et al.: Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004, 31:1829–1833.

    PubMed  CAS  Google Scholar 

  41. Kwok JS, Hui KH, Lee TL, et al.: Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34:359–366.

    Article  PubMed  CAS  Google Scholar 

  42. Machado SH, von Mühlen CA, Brenol JC, et al.: The prevalence of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. J Pediatr (Rio J) 2005, 81:491–494.

    Article  Google Scholar 

  43. Brunner J, Sitzmann FC: Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol 2006, 16:372–375.

    Article  PubMed  CAS  Google Scholar 

  44. Brunner J, Sitzmann FC: The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006, 24:449–451.

    PubMed  CAS  Google Scholar 

  45. Dewint P, Hoffman IE, Rogge S, et al.: Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2006, 45:204–208.

    Article  CAS  Google Scholar 

  46. Hall PJ, Burman SJ, Laurent MR, et al.: Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis 1986, 45:464–474.

    PubMed  CAS  Google Scholar 

  47. Ferucci ED, Majka DS, Parrish LA, et al.: Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005, 52:239–246.

    Article  PubMed  CAS  Google Scholar 

  48. Syed RH, Gilliam BE, Moore TL: Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2008, In press.

  49. Low JM, Chauhan AK, Moore TL: Abnormal kappa: lambda light chain ratio in circulating immune complexes as a marker for B cell activity in juvenile idiopathic arthritis. Scand J Immunol 2007, 65:76–83.

    Article  PubMed  CAS  Google Scholar 

  50. Vieira LM, d’Orse E, Periera IA, et al.: A comparison study of second and third generation anti-cyclic citrullinated peptide antibody ELISAs. Arthritis Rheum 2007, 56:S724.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Terry L. Moore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Syed, R.H., Gilliam, B.E. & Moore, T.L. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep 10, 156–163 (2008). https://doi.org/10.1007/s11926-008-0027-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0027-4

Keywords

Navigation